Literature DB >> 10861091

Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.

E J Wagar1, M A Cromwell, L D Shultz, B A Woda, J L Sullivan, R M Hesselton, D L Greiner.   

Abstract

Human PBMC engraft in mice homozygous for the severe combined immunodeficiency (Prkdcscid) mutation (Hu-PBL-scid mice). Hu-PBL-NOD-scid mice generate 5- to 10-fold higher levels of human cells than do Hu-PBL-C.B-17-scid mice, and Hu-PBL-NOD-scid beta2-microglobulin-null (NOD-scid-B2mnull) mice support even higher levels of engraftment, particularly CD4+ T cells. The basis for increased engraftment of human PBMC and the functional capabilities of these cells in NOD-scid and NOD-scid-B2mnull mice are unknown. We now report that human cell proliferation in NOD-scid mice increased after in vivo depletion of NK cells. Human cell engraftment depended on CD4+ cells and required CD40-CD154 interaction, but engrafted CD4+ cells rapidly became nonresponsive to anti-CD3 Ab stimulation. Depletion of human CD8+ cells led to increased human CD4+ and CD20+ cell engraftment and increased levels of human Ig. We further document that Hu-PBL-NOD-scid mice are resistant to development of human EBV-related lymphoproliferative disorders. These disorders, however, develop rapidly following depletion of human CD8+ cells and are prevented by re-engraftment of CD8+ T cells. These data demonstrate that 1) murine NK cells regulate human cell engraftment in scid recipients; 2) human CD4+ cells are required for human CD8+ cell engraftment; and 3) once engrafted, human CD8+ cells regulate human CD4+ and CD20+ cell expansion, Ig levels, and outgrowth of EBV-related lymphoproliferative disorders. We propose that the Hu-PBL-NOD-scid model is suitable for the in vivo analysis of immunoregulatory interactions between human CD4+ and CD8+ cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861091     DOI: 10.4049/jimmunol.165.1.518

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.

Authors:  Arnone Nithichanon; Louise J Gourlay; Gregory J Bancroft; Manabu Ato; Yoshimasa Takahashi; Ganjana Lertmemongkolchai
Journal:  Immunology       Date:  2017-02-09       Impact factor: 7.397

2.  Immunological characterization of human vaginal xenografts in immunocompromised mice: development of a small animal model for the study of human immunodeficiency virus-1 infection.

Authors:  T M Kish; L R Budgeon; P A Welsh; M K Howett
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 3.  Overcoming current limitations in humanized mouse research.

Authors:  Michael A Brehm; Leonard D Shultz; Jeremy Luban; Dale L Greiner
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

4.  Human natural regulatory T cell development, suppressive function, and postthymic maturation in a humanized mouse model.

Authors:  Takashi Onoe; Hannes Kalscheuer; Nichole Danzl; Meredith Chittenden; Guiling Zhao; Yong-Guang Yang; Megan Sykes
Journal:  J Immunol       Date:  2011-08-29       Impact factor: 5.422

5.  Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.

Authors:  Miguel Islas-Ohlmayer; Angela Padgett-Thomas; Rana Domiati-Saad; Michael W Melkus; Petra D Cravens; Maria del P Martin; George Netto; J Victor Garcia
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 6.  Human allograft rejection in humanized mice: a historical perspective.

Authors:  Michael A Brehm; Leonard D Shultz
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

7.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

8.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Authors:  Dawn A Maier; Andrea L Brennan; Shuguang Jiang; Gwendolyn K Binder-Scholl; Gary Lee; Gabriela Plesa; Zhaohui Zheng; Julio Cotte; Carmine Carpenito; Travis Wood; S Kaye Spratt; Dale Ando; Philip Gregory; Michael C Holmes; Elena E Perez; James L Riley; Richard G Carroll; Carl H June; Bruce L Levine
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

9.  Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.

Authors:  J Babad; G Mukherjee; A Follenzi; R Ali; B O Roep; L D Shultz; P Santamaria; O O Yang; H Goldstein; D L Greiner; T P DiLorenzo
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

10.  Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.

Authors:  M A King; L Covassin; M A Brehm; W Racki; T Pearson; J Leif; J Laning; W Fodor; O Foreman; L Burzenski; T H Chase; B Gott; A A Rossini; R Bortell; L D Shultz; D L Greiner
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.